PTC-028
- Product Name
- PTC-028
- CAS No.
- 1782970-28-8
- Chemical Name
- PTC-028
- Synonyms
- PTC-028;CS-1497;PTC028;PTC 028;PTC-028, 10 mM in DMSO;inhibit,Inhibitor,PTC 028,PTC-028,PTC028,Apoptosis;6-(5,6-Difluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrazinamine;2-Pyrazinamine, 6-(5,6-difluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]-;6-(5,6-Difluoro-2-methyl-1H-benzo[d]imidazol-1-yl)-N-(4-(trifluoromethyl)phenyl)pyrazin-2-amine
- CBNumber
- CB43370692
- Molecular Formula
- C19H12F5N5
- Formula Weight
- 405.32
- MOL File
- 1782970-28-8.mol
PTC-028 Property
- storage temp.
- Store at -20°C
- solubility
- DMF: 20 mg/ml; DMSO: 1 mg/ml
- form
- A solid
- color
- White to off-white
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- BP168106
- Product name
- PTC 028
- Packaging
- 10mg
- Price
- $135
- Updated
- 2021/12/16
- Product number
- 6692DW
- Product name
- 6-(5,6-Difluoro-2-methylbenzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrazin-2-amine
- Packaging
- 10mg
- Price
- $232
- Updated
- 2021/12/16
- Product number
- INB0009856
- Product name
- PTC-028
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $457.57
- Updated
- 2021/12/16
- Product number
- BP168106
- Product name
- PTC 028
- Packaging
- 50mg
- Price
- $472.5
- Updated
- 2021/12/16
- Product number
- DC7552
- Product name
- PTC-028
- Purity
- >98%
- Packaging
- 1g
- Price
- $2000
- Updated
- 2021/12/16
PTC-028 Chemical Properties,Usage,Production
Uses
PTC-028 is an orally bioavailable inhibitor of stem cell factor BMI-1 in ovarian cancer. PTC-028 selectively inhibits cancer cells whereas normal cells remain unaffected. PTC-028 downregulates BMI-1, inducing caspase-mediated apoptosis[1].
in vivo
PTC-028 (15 mg/kg; administered orally twice weekly) causes ~94% (0.169 g) reduction in tumor weight compared to the control (average tumor weight, ~3g) [1].
?
No obvious toxicity is noted in the animals during therapy experiments as assessed by mean body weight[1].
?
PTC-028 (10 mg/kg or 20mg/kg; single oral doses) is administrated to the CD-1 mice. The Cmax is reached at both dose levels 1h post dose after which plasma concentrations slowly reduce[1].
| Animal Model: | Female athymic nude mice with implanted OV90 cells[1] |
| Dosage: | 15 mg/kg |
| Administration: | Orally administered; twice weekly |
| Result: | Caused ~94% (0.169 g) reduction in tumor weight. |
| Animal Model: | Female CD-1 mice[1] |
| Dosage: | 10 mg/kg or 20mg/kg |
| Administration: | Oral administered; single dose |
| Result: | Total plasma AUC0-24h were 10.9 and 26.1 μg?h/mL at doses of 10 and 20 mg/kg. The Cmax for PTC-028 at 10 and 20 mg/kg was 0.79 and 1.49 ug/mL, respectively. |
References
[1] Dey A, et al. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 Jan;17(1):39-49. DOI:10.1158/1535-7163.MCT-17-0574
PTC-028 Preparation Products And Raw materials
Raw materials
Preparation Products
PTC-028 Suppliers
- Tel
- --
- Fax
- --
- sales@ajchem.in
- Country
- India
- ProdList
- 6100
- Advantage
- 58